NCT05011227

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

A Prospective, Single-arm, Multi-center Clinical Study of Camrelizumab and Chemotherapy Combined With Endoscopic Surgery in the Treatment of Recurrent Nasopharyngeal Carcinoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Eye & ENT Hospital of Fudan University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To explore the effect of Camrelizumab and chemotherapy combining with endoscopic surgery in the treatment of recurrent nasopharyngeal carcinoma.

Conditions

• Recurrent Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
DRUG	Camrelizumab	2 cycles Camrelizumab before endoscopic surgery and one year after
DRUG	Chemotherapy	2 cycles Gemcitabine based chemotherapy before endoscopic surgery, with or without after surgery
PROCEDURE	endoscopic surgery	standard endoscopic surgery for recurrent nasopharyngeal carcinoma

Timeline

• Start date: 2021-08-10
• Primary completion: 2025-08-10
• Completion: 2025-08-10
• First posted: 2021-08-18
• Last updated: 2024-03-06

Locations

7 sites across 1 country: China